Contact
Please use this form to send email to PR contact of this press release:
Pluristem’s Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory Agency
TO:
Please use this form to send email to PR contact of this press release:
Pluristem’s Pivotal Phase III Critical Limb Ischemia Trial Approved by UK Regulatory Agency
TO: